Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2024-2032
세계 알파 1 항트립신 결핍증 치료 시장 규모는 2023년 20억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 2024-2032년 사이 7.6%의 연평균 성장률(CAGR)로 40억 달러에 달할 것으로 예상하고 있습니다.
알파 1 항트립신(AAT) 결핍증은 체내에서 AAT 단백질이 충분히 생성되지 않는 유전적 질환을 말하며, AAT 단백질은 폐와 간을 다른 단백질의 악영향으로부터 보호하는 데 필수적입니다. AAT 결핍이 심한 환자는 간경화, 만성폐쇄성폐질환(COPD), 폐기종이 발생할 수 있습니다. 유전자 검사나 혈액 검사로 진단할 수 있습니다. 치료법으로는 기관지확장제, 부신피질 스테로이드 등의 약물을 정맥주사 또는 흡입하는 강화요법, 폐 재활치료, 산소요법 등이 있습니다.
호흡기 질환의 유병률 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 또한, 강화 요법이 널리 채택되고 있는 것도 시장 성장을 촉진하고 있습니다. 이 치료법은 건강한 기증자의 혈장에서 AAT 단백질을 추출하여 환자의 호흡기 내 AAT 농도를 증가시킵니다. 이에 따라 이 치료법은 폐기종의 진행을 늦추고 악화 빈도를 최소화하며 회복 속도를 향상시킵니다. 또한, 진단 방법의 다양한 기술적 진보와 AAT의 제조 및 정제 과정에서 혁신적인 공정의 개발은 다른 성장 촉진요인으로 작용하고 있으며, AAT는 품질이 향상되고 바이러스 및 박테리아 등의 오염 물질이 포함되어 있지 않습니다. 이 외에도 광범위한 연구개발(R&D) 활동, 의료 인프라 개선 등이 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 다루는 주요 질문들
- 세계 알파 1 항트립신 결핍증 치료 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
- COVID-19는 전 세계 알파 1 항트립신 결핍증 치료 시장에 어떤 영향을 미쳤을까?
- 주요 지역 시장이란?
- 치료 유형별 시장 현황은?
- 투여 경로별 시장 현황은?
- 최종사용자별 시장 분석은?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 알파 1 항트립신 결핍증 치료 시장 구조와 주요 진출 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 알파 1 항트립신 결핍증 치료 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 치료 유형별
- 증강 요법
- 기관지확장제
- 코르티코스테로이드
- 산소요법
- 기타
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- AstraZeneca PLC
- C.H. Boehringer Sohn AG & Ko. KG
- CSL Limited
- GlaxoSmithKline Plc
- Grifols S.A.
- Kamada Ltd.
- LFB Biomedicaments S.A.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
ksm
The global alpha 1 antitrypsin deficiency treatment market size reached US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032.
Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.
The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor's blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha 1 antitrypsin deficiency treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type, route of administration and end user.
Breakup by Treatment Type:
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
Others
Breakup by Route of Administration:
Parenteral
Inhalation
Oral
Breakup by End User:
Hospitals
Specialty Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
- How has the global alpha 1 antitrypsin deficiency treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global alpha 1 antitrypsin deficiency treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global alpha 1 antitrypsin deficiency treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Alpha 1 Antitrypsin Deficiency Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Augmentation Therapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Bronchodilators
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Corticosteroids
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Oxygen Therapy
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Parenteral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Inhalation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Oral
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AstraZeneca PLC
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 C.H. Boehringer Sohn AG & Ko. KG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 CSL Limited
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 GlaxoSmithKline Plc
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Grifols S.A.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Kamada Ltd.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 LFB Biomedicaments S.A.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Takeda Pharmaceutical Company Limited
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Teva Pharmaceutical Industries Ltd.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
